Page 155 - Cardiac Nursing

8:2
009
9/2
P
M
5 A
qxd
1-1
p11
9/0
31.
0
0-c
05_
L L LWB K34 0-c 05_ p11 1-1 31. qxd 0 9/0 9/2 009 0 0 8:2 5 A M P a a g e 1 31 Apt ara
LWBK340-c05_p111-131.qxd 09/09/2009 08:25 AM Page 131 Aptara
K34
LWB
e 1
g
31
ara
Apt
C HAPTER 5 / Atherosclerosis, Inflammation, and Acute Coronary Syndrome 131
219. Haverkate, F., Thompson, S. G., Pyke, S. D., et al. (1997). Production 239. Asano, G., Takashi, E., Ishiwata, T., et al. (2003). Pathogenesis and pro-
of C-reactive protein and risk of coronary events in stable and unstable tection of ischemia and reperfusion injury in myocardium. Journal of
angina. European Concerted Action on Thrombosis and Disabilities Nippon Medical School, 70, 384–392.
Angina Pectoris Study Group. Lancet, 349, 462–466. 240. Marczin, N., El-Habashi, N., Hoare, G. S., et al. (2003). Antioxidants
220. Morrow, D. A., Rifai, N., Antman, E. M., et al. (1998). C-reactive pro- in myocardial ischemia-reperfusion injury: Therapeutic potential and
tein is a potent predictor of mortality independently of and in combi- basic mechanisms. Archives of Biochemistry and Biophysics, 420,
nation with troponin T in acute coronary syndromes: A TIMI 11A sub- 222–236.
study. Thrombolysis in Myocardial Infarction. Journal of the American 241. Kaur, J., Woodman, R. C., & Kubes, P. (2003). P38 MAPK: Critical
College of Cardiology, 31, 1460–1465. molecule in thrombin-induced NF-kappa B-dependent leukocyte re-
221. Ruggeri, Z. M. (1997). von Willebrand factor. Journal of Clinical Inves- cruitment. American Journal of Physiology, Heart and Circulatory Physiol-
4
tigations, 99, 559–564. ogy, 284, H1095–H1103.
4
222. Ruggeri, Z. M. (1992). von Willebrand factor as a target for antithrom- 242. Squadrito, F., Deodato, B., Squadrito, G., et al. (2003). Gene transfer of
6
botic intervention. Circulation, 86, III26–III29. IkappaBalpha limits infarct size in a mouse model of myocardial is-
6
223. Folsom, A. R. (2001). Hemostatic risk factors for atherothrombotic dis- chemia-reperfusion injury. Laboratory Investment, 83, 1097–1104.
6
ease: An epidemiologic view. Thrombosis and Haemostasis, 86, 366–373. 243. Kubes, P., Payne, D., & Ostrovsky, L. (1998). Preconditioning and
6
224. Meade, T. W., Cooper, J. A., Stirling, Y., et al. (1994). Factor VIII, ABO adenosine in I/R-induced leukocyte-endothelial cell interactions. Amer-
4
4
blood group and the incidence of ischaemic heart disease. British Jour- ican Journal of Physiology, 274, H1230–H1238.
nal of Haematology, 88, 601–607. 244. Hein, T. W., Zhang, C., Wang, W., et al. (2003). Ischemia-reperfusion
R
R
225. Rumley, A., Lowe, G. D., Sweetnam, P. M., et al. (1999). Factor VIII, von selectively impairs nitric oxide-mediated dilation in coronary arterioles:
Willebrand factor and the risk of major ischaemic heart disease in the Counteracting role of arginase. FASEB Journal, 17, 2328–2330.
7
7
Caerphilly Heart Study. British Journal of Haematology, 105, 110–116. 245. Yue, T. L., Bao, W., Jucker, B. M., et al. (2003). Activation of peroxi-
226. Jansson, J. H., Nilsson, T. K., & Johnson, O. (1991). von Willebrand some proliferator-activated receptor-alpha protects the heart from is-
factor in plasma: A novel risk factor for recurrent myocardial infarction chemia/reperfusion injury. Circulation, 108, 2393–2399.
6
6
and death. British Heart Journal, 66, 351–355. 246. Kloner, R. A. (1993). Does reperfusion injury exist in humans? Journal
227. Thogersen, A. M., Jansson, J. H., Boman, K., et al. (1998). High plas- of the American College of Cardiology, 21, 537–545.
minogen activator inhibitor and tissue plasminogen activator levels in 247. Feigl, E. O. (1998). Neural control of coronary blood flow. Journal of
plasma precede a first acute myocardial infarction in both men and Vascular Research, 35, 85–92.
women: Evidence for the fibrinolytic system as an independent primary 248. Antman, E. M., Tanasijevic, M. J., Thompson, B., et al. (1996). Car-
risk factor. Circulation, 98, 2241–2247. diac-specific troponin I levels to predict the risk of mortality in patients
228. Dankner, R., Goldbourt, U., Boyko, V., et al. (2003). Predictors of car- with acute coronary syndromes. New England Journal of Medicine, 335,
diac and noncardiac mortality among 14,697 patients with coronary 1342–1349.
heart disease. American Journal of Cardiology, 91, 121–127. 249. Brogan, G. X., Jr., Vuori, J., Friedman, S., et al. (1996). Improved speci-
229. Carter, K. W., Hung, J., Powell, B. L., et al. (2008). Association of In- ficity of myoglobin plus carbonic anhydrase assay versus that of creatine
terleukin-1 gene polymorphisms with central obesity and metabolic syn- kinase-MB for early diagnosis of acute myocardial infarction. Annals of
7
7
drome in a coronary heart disease population. Human Genetics, 124(3), Emergency Medicine, 27, 22–28.
199–206. 250. Pierard, L. A. (2003). Assessing perfusion and function in acute my-
230. Qasim, A. N., Metkus, T. S., Tadesse, M., et al. (2008). Resistin gene ocardial infarction: How and when? Heart, 89, 701–703.
variation is associated with systemic inflammation but not plasma 251. Namiki, A., Kubota, T., Fukazawa, M., et al. (2003). Endothelin-1 con-
adipokine levels, metabolic syndrome or coronary atherosclerosis in centrations in pericardial fluid are more elevated in patients with is-
non-diabetic Caucasians. Clinical Endocrinology (Oxford). Epub ahead of chemic heart disease than in patients with nonischemic heart disease.
print. Japan Heart Journal, 44, 633–644.
4
4
231. Harrap, S. B., Zammit, K. S., Wong, Z. Y., et al. (2002). Genome-wide 252. Jugdutt, B. I. (2003). Ventricular remodeling after infarction and the ex-
linkage analysis of the acute coronary syndrome suggests a locus on chro- tracellular collagen matrix: When is enough enough? Circulation, 108,
mosome 2. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 1395–1403.
874–878. 253. Pfeffer, M. A. (1995). Left ventricular remodeling after acute myocardial
232. Tang, W., Miller, M. B., Rich, S. S., et al. (2003). Linkage analysis of a infarction. Annual Review of Medicine, 46, 455–466.
6
6
composite factor for the multiple metabolic syndrome: The National 254. Ren, G., Dewald, O., & Frangogiannis, N. G. (2003). Inflammatory
Heart, Lung, and Blood Institute Family Heart Study. Diabetes, 52, mechanisms in myocardial infarction. Current Drug Targets – Inflamma-
2840–2847. tion and Allergy, 2, 242–256.
233. Connelly, J. J., Shah, S. H., Doss, J. F., et al. (2008). Genetic and func- 255. Ferroni, P., Basili, S., Martini, F., et al. (2003). Serum metalloproteinase
tional association of FAM5C with myocardial infarction. BMC Medical 9 levels in patients with coronary artery disease: A novel marker of in-
Genetics, 9, 33. flammation. Journal of Investigation Medicine, 51, 295–300.
234. Ozdemir, O., Gundogdu, F., Karakelleoglu, S., et al. (2008). Compari- 256. Klein, R. F., Troyer, W. G., Thompson, H. K., et al. (1968). Cate-
son of serum levels of inflammatory markers and allelic variant of inter- cholamine excretion in myocardial infarction. Archives of Internal Medi-
leukin-6 in patients with acute coronary syndrome and stable angina cine, 122, 476–482.
pectoris. Coronary Artery Diseases, 19, 15–19. 257. Gershlick, A. H., & More, R. S. (1998). Treatment of myocardial in-
6
235. Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., et al. (2008). Poly- farction. BMJ, 316, 280–284.
6
T
T
morphism in KIF6 gene and benefit from statins after acute coronary 258. Galcera-Tomas, J., Castillo-Soria, F. J., Villegas-Garcia, M. M., et al.
syndromes: Results from the PROVE IT-TIMI 22 study. Journal of the (2001). Effects of early use of atenolol or captopril on infarct size and
American College of Cardiology, 51, 449–455. ventricular volume: A double-blind comparison in patients with anterior
236. Braunwald, E., Antman, E. M., Beasley, J. W., et al. (2000). ACC/AHA acute myocardial infarction. Circulation, 103, 813–819.
guidelines for the management of patients with unstable angina and non- 259. McDonough, J. L., Labugger, R., Pickett, W., et al. (2001). Cardiac tro-
ST-segment elevation myocardial infarction. A report of the American ponin I is modified in the myocardium of bypass patients. Circulation,
College of Cardiology/American Heart Association Task Force on Practice 103, 58–64.
Guidelines (Committee on the Management of Patients With Unstable 260. Ishikawa, T., Hatakeyama, K., Imamura, T., et al. (2003). Involvement
Angina). Journal of the American College of Cardiology, 36, 970–1062. of C-reactive protein obtained by directional coronary atherectomy in
6
6
237. Dispersyn, G. D., & Borgers, M. (2001). Apoptosis in the heart: About plaque instability and developing restenosis in patients with stable or un-
6
6
programmed cell death and survival. News in Physiological Sciences, 16, stable angina pectoris. American Journal of Cardiology, 91, 287–292.
41–47. 261. Dollery, C. M., McEwan, J. R., & Henney, A. M. (1995). Matrix met-
7
7
238. Isner, J. M., Kearney, M., Bortman, S., et al. (1995). Apoptosis in hu- alloproteinases and cardiovascular disease. Circulation Research, 77,
man atherosclerosis and restenosis. Circulation, 91, 2703–2711. 863–868.